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Background: The insulin receptor exists as two isoforms: IRA and IRB.
Results: IRA and IRB are similarly matured by furin, but when furin activity is reduced, IRB is matured by PACE4.
Conclusion: Proprotein convertase inhibition can selectively reduce IRA maturation and its signaling.
Significance: This can be considered as a new opportunity to target IRA signaling in cancer.
Gaining the full activity of the insulin receptor (IR) requires
the proteolytic cleavage of its proform by intra-Golgi furin-like
activity. In mammalian cells, IR is expressed as two isoforms
(IRB and IRA) that are responsible for insulin action. However,
only IRA transmits the growth-promoting andmitogenic effects
of insulin-like growth factor 2. Here we demonstrate that the
two IR isoforms are similarly cleaved by furin, but when this
furin-dependent maturation is inefficient, IR proforms move to
the cell surface where the proprotein convertase PACE4 selec-
tively supports IRB maturation. Therefore, in situations of
impaired furin activity, the proteolytic maturation of IRB is
greater than that of IRA, and accordingly, the amount of phos-
phorylated IRB is also greater than that of IRA.Wehighlight the
ability of a particular proprotein convertase inhibitor to effec-
tively reduce thematuration of IRA and its associatedmitogenic
signaling without altering the signals emanating from IRB. In
conclusion, the selective PACE4-dependent maturation of IRB
occurs when furin activity is reduced; accordingly, the pharma-
cological inhibition of furin reduces IRA maturation and its
mitogenic potential without altering the insulin effects.
The mature insulin receptor (IR)5 is a heterotetrameric
transmembrane protein composed of two disulfide-linked dim-
mers, each of which has an amino-terminal ligand-binding 
subunit and a carboxyl-terminal tyrosine kinase active  sub-
unit (for review, see Ref. 1). The  and  subunits are synthe-
sized as a single precursor polypeptide (proIR) that is cleaved
after being transported to the Golgi compartments (2) on the
carboxyl side of the tetrabasic amino acid sequence (Arg-Lys-
Arg-Arg735) located at the junction between the two subunits
(3, 4). The physiological importance of proteolytic proIR mat-
urationwas demonstrated in patients whowere sufferingmajor
insulin-resistant diabetes because of an Arg7353 Ser substitu-
tion at the proIR processing site (5, 6). Moreover, a processing
defect in the proIR was observed in the livers of a particular
animal model for diabetes (7).
Furin is a proprotein convertase (PC) that is concentrated in
the trans-Golgi network and efficiently cleaves protein precur-
sors. Many transmembrane receptors that are cleaved by furin
contain the minimum cleavage site motif Arg-Xaa-[Lys/Arg]-
Arg2 (for review see, Ref. 8), and naturally, furin has emerged
as the PC that is predominantly responsible for cleaving proIR
(9–11). However, proIR proteolyticmaturation is still observed
in furin-deficient cells and in mice with a liver-specific furin
knock-out (12, 13), suggesting that other endoproteases can
substitute furin for this maturation step. Consistent with this
interpretation, the proteolytic maturation of a truncated solu-
ble form of insulin receptor was increased upon PACE4 over-
expression in furin-deficient cells (14).
IR exists as two isoforms, namely IRA and IRB, which are
derived from the alternative splicing of exon 11 in the primary
transcript (15). As a consequence, IRA lacks and IRB contains a
12-amino acid segment located in the carboxyl terminus of the
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 subunit that is close to the aforementioned proreceptor pro-
cessing site (three residues before the carboxyl terminus of the
-chain). The relative abundance of the two splice variants is
regulated in a tissue-specific manner (for review, see Ref. 16).
IRA is ubiquitously expressed and is preponderant in fetal and
cancer tissues, whereas IRB is predominantly expressed in tar-
get tissues of the insulin metabolic effects. The two IR isoforms
present subtle differences in terms of activation and signaling.
IRA is a high affinity receptor for insulin but also for IGF2 (17,
18) and IGF1 (19). It displays faster internalization and recy-
cling kinetics (20, 21), which could explain its higher propensity
for signal proliferation and survival in comparison with IRB
(16). Furthermore, selective insulin signaling through IRA and
IRB that regulates transcription of insulin and glucokinase
genes was demonstrated in pancreatic  cells (22). This selec-
tivity was believed to result from IR isoform-mediated signaling
from different plasma membrane microdomains (23, 24).
A seminal study has demonstrated that both proIR isoforms
are similarly matured in vitro by recombinant furin (25). How-
ever, an exhaustive statistical analysis of furin cleavage sites
interpreted within the three-dimensional crystal structure of
the furin catalytic domain revealed that the actual furin cleav-
age site stretches far beyond the tetrabasic consensus sequence
and contains up to 20 amino acids (26). This sequence encom-
passes 10 amino acids of IRB exon 11, indicating that the IRA
and IRB furin recognition sites are different.
We have investigated the cellular proteolytic maturation of
IRA and IRB. Our data clearly show that even though furin is
predominantly responsible for the maturation of the two insu-
lin proreceptor isoforms, it is not essential for IRB maturation.
IRB maturation can be achieved at the cell surface by PACE4.
We took advantage of this difference in IRA and IRB matura-
tion to demonstrate that it is possible to reduce the mitogenic
signals emanating from the IR by inhibiting IRA maturation.
EXPERIMENTAL PROCEDURES
Reagents—The PC inhibitors decanoyl-Arg-Val-Lys-Arg-
chloromethylketone (dec-RVKR-cmk) and tripeptide deriva-
tive phenylacetyl-Arg-Val-Arg-4-amidinobenzylamide (Phac-
RVR-4-Amba) were purchased from Merck. The PC inhibitor
multileucine peptide (ML) and its cell-impermeable PEGylated
derivative (PEG8-ML) were previously described (27). Insulin
receptor antibodies were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA) ( chain, sc711; chain, sc7953; phos-
phorylated  chain (Tyr1162/11636), sc25103). PKB and Erk1/2,
pan and phosphospecific antibodies were purchased from Cell
Signaling Technology (Danvers, MA). The His6 antibody was
purchased fromGeneTex (Irvine, CA). FlagM2 antibody, insu-
lin, and IGF2 were purchased from Sigma-Aldrich. Phospho-
Erk1/2 and phospho-PKB ELISA kits were purchased from
eBioscience (San Diego, CA). Anti-furin monoclonal (Mon-
152) and anti-PC7 polyclonal antibodies were produced by
John Creemers.
Expression Vectors—The expression vectors for IRA, IRB, an
uncleavable form of IR, furin, PC7, PACE4, PC5/6A, PC5/6B,
1-PDX, and EK4 were all described elsewhere (22, 28–32).
The vectors for human furin and PC7 shRNA were described
previously (33).
Cell Culture and Transfection—The human cell lines HeLa,
LoVo, HEK293, and the murine cell line 3T3L1 were main-
tained in culture as described by ATCC. The adipocyte differ-
entiation of 3T3L1 cells was performed as previously described
(34). Transient cell transfection was performed with PolyJet
reagent (SignaGene Laboratories, Rockville, MD) as specified
by the manufacturer.
Enzymatic Deglycosylation—N-Linked carbohydrate resi-
dues were removed by incubating the cell lysates for 2 h at 37 °C
with 1000 units of either peptide-N-glycosidase F or endogly-
cosidaseH (NewEngland Biolabs, Beverly,MA) as described by
the manufacturer.
Cell Surface Protein Isolation—The cell surface protein iso-
lation kit was used as described by themanufacturer (Pierce). In
brief, LoVo cells werewashed four timeswith ice-cold PBS. The
membrane-impermeable biotinylation reagent EZ-Link Sulfo-
NHS-SS-Biotin was added to a final concentration of 100 M,
and the cells were incubated on ice for 30 min. The biotinyla-
tion reaction was stopped by adding the quenching solution
followed by two PBS washes. The cells were lysed, and labeled
proteins were isolated with NeutrAvidin-agarose resin. Pro-
teins were eluted from the resin and analyzed by immunoblot.
Immunoblot—Total cell lysates were separated on 4–12%
gradient NuPAGE gels with MOPS SDS running buffer (Invit-
rogen) and transferred to polyvinylidene fluoride membranes.
The membranes were blocked for 1 h in 5% BSA solution, and
the proteins were immunodetected with the appropriate anti-
bodies. Image acquisition was performed by using a chemilu-
minescent CCD imager Image Quant LAS 4000 (GE Health-
care). A densitometric analysis of the bands corresponding to
the proform andmature form of IR (proIR and IR, respectively)
was performed with the ImageQuant TL software (GE Health-
care), and IR proteolytic maturation was calculated as the
IR/proIR ratio.
Measuring Furin Activity—Intra-Golgi furin activity was
monitored with the GRAPfurin reporter construct (35). 48 h
after transient transfection, the cell medium was replaced by
uncoloredDMEM for an incubation period of 5 h. Themedium
was centrifuged at 20,000 g, mixedwith the alkaline phospha-
tase substrate para-nitrophenyl phosphate in a 96-well plate,
and incubated 1 h for color development, and then the absor-
bance was read at 405 nm. The values were normalized to those
obtained from empty vector-transfected cells.
Glut4 Translocation Assay—The fluorescence-based assay
for the detection of cell surface GLUT4 levels has been
described previously (36).
2-Deoxy-D-glucose Uptake Assay—Glucose uptake activity of
3T3L1 adipocytes was measured by the chemiluminescent
assay (37) using Glucofax kit as described by the manufacturer
(Yelen, Ensues la Redonne, France).
Real Time PCR Analysis—Total RNA was extracted using a
Nucleospin RNA kit (Macherey-Nagel, Hoerdt, France), cDNA
was synthesized from 0.5 g of RNA using. Moloney murine
leukemia virus reverse transcriptase (Invitrogen) was used for
PCR amplification. RT-PCRs were performed on the Light-
Cycler 480 instrument (Roche Applied Science) using the Eva
Green MasterMix (Euromedex, Souffelweyersheim, France).
The comparative Ct method (2(CT)) was used to calculate
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the relative differences in mRNA expression. The acidic ribo-
somal phosphoprotein P0 (Rplp0) was used as housekeeping
gene. Primers sequences are available upon request.
Cell Proliferation Assay—Cell proliferation was determined
using the DELFIA proliferation assay kit (PerkinElmer Life Sci-
ences) according to the manufacturer’s instructions. Briefly,
HEK293 cells were transfected in 6-well plate, 12 h after they
were detached using Accutase (GE Healthcare Europe, Velizy-
Villacoublay, France) and seeded into a 96-well white walled
plate at a density of 4000 cells/well. After complete adhesion,
cells were serum-starved (0.5% FBS) overnight and then treated
with Phac-RVR-4-Amba or vehicle for 4 h before the addition
of BrdU and insulin or IGF2. Cells were incubated for an addi-
tional 16 h, fixed, and incubated with anti-BrdU labeled with
europium for 90 min. Time-resolved fluorescence was meas-
ured at 340-nm excitation and 615-nm emission.
Statistical Analyses—All data were analyzed with GraphPad
Prism software. The applied test was described in the figure
legends or in the text. Statistical significancewas set at p 0.05.
RESULTS
In the Absence of Furin, IRB Proteolytic Maturation Is Higher
than That of IRA—The use of a computational tool for predict-
ing furin cleavage sites (PiTou software) that was developed
based on the functional characterization of the 20-residue rec-
ognition sequencemotif (38) revealed that both proIR isoforms
can be cleaved by furin at the unique expected site (Arg735 for
IRB and Arg723 for IRA) with similar efficiencies. Consistent
with this prediction, comparable amounts of immature and
mature IRA and IRB forms were detected in the lysates of HeLa
cells that independently overexpressed either of these isoforms
(Fig. 1A); consequently, the proteolytic maturation of both IR
isoforms, which was calculated as the IR/proIR ratio, was not
significantly different. However, when IRA and IRB were over-
expressed in furin-deficient LoVo cells, the mature IRB was
detected in larger amounts than that of IRA, and their proform
quantities were comparable (Fig. 1B). As a consequence, the
IRB proteolytic maturation was significantly greater (2.17 
0.75-fold) than that of IRA. It should be noted that the overex-
pressed IRA had still matured a bit. The re-expression of furin
in LoVo cells increased thematuration (increases in themature
form and decreases in proIR) of both proIR isoforms to the
same level (Fig. 1C), rendering the maturation of IRA and IRB
comparable. Consistent with this result, a furin knockdown in
HeLa cells more substantially reduced the proteolytic matura-
tion of IRA than that of IRB (Fig. 1D), so the maturation of IRB
was significantly greater (1.61  0.27-fold; p  0.015; n  7)
than that of IRA. It should be emphasized that the transfection
efficiencywas50–60% (data not shown) and that furin detec-
tionwasmade on thewhole cell preparation,which explains the
apparent low reduction of the furin amount by the shRNA. As a
logical consequence of the significant reduction of the mature
IRA isoform in furin knockdown cells, the amount of its phos-
phorylated form in response to insulin treatment was propor-
tionally reduced (Fig. 1E). These data demonstrate that furin is
responsible formost of the proIR proteolyticmaturation. How-
ever, in the absence of furin, IRA and IRB maturation is differ-
ently regulated.
In the Absence of Furin, IRB Proform Is Exposed at the Cell
Surface—Immunoblot analysis revealed that the proIR
expressed in LoVo cells appeared as a doublet (Fig. 1B), and
furin overexpression led to the disappearance of the upper band
of the doublet (Fig. 1C). This doublet appeared also upon furin
FIGURE 1. The importance of furin in IRmaturation.A and B, HeLa (A) or LoVo (B) cells were transfectedwith an empty vector orwith an IRA or IRB expression
vector (	). C, LoVo cells were transfected with an IRA or IRB expression vector (	) in association with a furin (fur) expression vector. D, HeLa cells were
transfectedwith an IRA or IRB expression vector (	) in association with untargeted shRNA (shscr) or furin-specific shRNA (shfur). E, HeLa cells were transfected
as in D, 48 h after they were stimulated with insulin (1 nM) for 10min. IR and furin were analyzed by immunoblot: proIR, IR, and pIR indicate the positions of
theproform, themature form ( chain), and thephosphorylated form ( chain) of IR, respectively; fur indicates thepositionof furin. The lower panel inB is a long
exposure of the immunoblot showing the mature form of IR (IR). The graphs in A and B show the maturation of IRA and IRB (calculated as described under
“Experimental Procedures”) in six different experiments; data from the same experiment are connected by lines. The p values (Wilcoxon test) are indicated.
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knockdown in furin-expressing cells (Fig. 1D). Furthermore,
the proform of a mutated IR that cannot be proteolyzed by PCs
was also detected as a doublet (Fig. 2A), indicating that this
doublet originates from inefficient proIR proteolytic matura-
tion. In LoVo cells, the slowmigrating proform of IR (the upper
band of the proIR doublet) was exposed at the cell surface,
as demonstrated by cell surface biotinylation (Fig. 2B). As
expected, furin overexpression reduced the amount of cell sur-
face-exposed proIR and increased the amount of mature IR.
Deglycosylation experiments confirmed that the slow migrat-
ing proform of IR crossed the Golgi apparatus because it was
endoglycosidase H-resistant, whereas the endoglycosidase
H-sensitive fast migrating proIR was in the endoplasmic retic-
ulum (Fig. 2C). As a control, both proIR forms were deglycosy-
lated by peptide-N-glycosidase F treatment. The 3T3L1 adi-
pocytes express comparable amounts of IRA and IRB mRNA
(Fig. 2D) and produce detectable amount of endogenous IR.
Treating these cells with the general potent irreversible PC
inhibitor (dec-RVKR-cmk) reduced IRmaturation and enabled
the slowmigrating proform of IR to appear (Fig. 2E), indicating
that cell surface exposure of the IR proform in response to PC
inhibition is not caused by a side effect of IR overexpression.
These results indicate that when proIR is not efficiently cleaved
by furin in the Golgi apparatus, it is still routed to the cell sur-
face. It is important to note that furin knockdown in HeLa cells
reducedmore efficiently the proteolyticmaturation of IRA than
that of IRB (Fig. 1D) and also increased the amount of the slow
migrating proform of IRA to a greater extent than that of IRB.
This observation is in accordance with the more exclusive
involvement of furin in the proteolytic maturation of IRA than
that of IRB. We also note that in LoVo cells, although IRA and
IRB are differently matured, there was no obvious difference in
the amount of their slow migrating proforms (Fig. 1, B and C),
suggesting that in these cells the furin-independentmaturation
of IR is rather low.
In theAbsence of Furin, IRBUndergoesConvertase-dependent
Proteolytic Maturation—We investigated whether a PC other
than furin could be responsible for IRB maturation. Treating
furin-deficient LoVo cells with the general PC inhibitor dec-
RVKR-cmk reduced the proteolyticmaturation of IRB, whereas
the low level of IRA maturation was barely reduced (Fig. 3A).
This result demonstrates that a PC other than furin is respon-
sible for IRB proteolytic maturation. However, IR maturation
that persists after dec-RVKR-cmk treatment suggests that, in
our conditions, either dec-RVKR-cmk does not inhibit all the
PCs responsible for the proteolytic maturation of IR or that the
remainingmaturation of IR is PC-independent. To clarify these
issues, we used the PC suicide substrate inhibitors1-PDX (29)
and EK4 (30) (two engineered1-antitrypsin serpinwith differ-
entmutation in the recognition site). In HeLa cells, EK4 proved
to be a slightly better furin inhibitor than 1-PDX (Fig. 3B).
Interestingly, the maturation of IRA, which is more exclusively
under the control of furin than that of IRB, was similarly
reduced by 1-PDX and EK4 (Fig. 3C), whereas thematuration
of IRB was significantly more reduced by EK4 than by 1-PDX.
We conclude that 1-PDX and EK4 are both effective inhibi-
tors of the furin-dependent maturation of IR, but in addition,
EK4 inhibits other PCs involved in IRB maturation. In LoVo
cells, overexpression of EK4 reduced the furin-independent
maturation of IRA and IRB (Fig. 3D) meaning that, in the
absence of furin, a PC activity is still responsible for at least a
part of the low level of IRA maturation.
These results further emphasize that the proteolytic matura-
tion of IRA is more exclusively under the control of furin than
that of IRB. They also show that in the absence of furin, the
residual maturation of IRB (and to a lesser extent that of IRA)
involves another PC activity.
PACE4 Is Responsible for the Cell Surface Furin-independent
Maturation of IRB—ProIR proteolyticmaturationwas analyzed
in LoVo cells overexpressing the PCs that exhibit a substantial
degree of functional redundancy with furin (39). Only the over-
expression of PACE4more efficiently increased thematuration
of the IRB than that of IRA (Fig. 4, A and B). In addition, a
reduction in the amount of the slow migrating proform of IRB
was observed (Fig. 4B). This result supports the involvement of
PACE4 in the enhanced maturation of the IRB proform in the
absence of furin. Unexpectedly, overexpressed PC7, PC5/6A,
and PC5/6B increased thematuration of both proIR isoforms as
FIGURE 2. The cellular localization of the IR proform. A, HeLa cells were
transfected with an empty vector or with vectors coding for IRB or for a
mutated form of IRB (IRBnc) that cannot be cleaved by PC. B, LoVo cells were
cotransfected with IRB together with an empty vector or with a furin expres-
sion vector (	), and the cells were surface-biotinylated. The total (left panel)
and cell surface (right panel) proteins were treated for immunoblot. C, lysates
of LoVo cells expressing IRB alone or in association with furin were mock
treated or treated for deglycosylationwith peptide-N-glycosidase F (pNGase)
or endoglycosidase H (endoH). D, mRNA levels of IR, IRA, and IRB were mea-
sured by quantitative PCR in 3T3L1 adipocytes (data are expressed as
means S.D.; n 5; the mean basal IR expression was set at 100). E, 3T3L1
adipocytes were treated or not with dec-RVKR-cmk (RVKR; 5M) for 12 h. The
IR was analyzed by immunoblot with IR antibody.
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efficiently as furin (Fig. 4A). However, these PCs cleaved both
proIR isoforms with the same efficiency, which does not sup-
port their role in the furin-independent maturation of the IRB
proform. Furthermore, in LoVo cells, knockdown of PC7,
which is the PC that is most similar to furin in terms of primary
structure and subcellular localization, did not change the mat-
uration of the IRB proform (Fig. 4C). PC5/6 is not expressed in
HeLa cells (Table 1) and thus cannot be responsible for the
differential maturation of IRA and IRB observed after furin
knockdown (Fig. 1D). Taken together, these data suggest that
the overexpression of PC7 and PC5/6 allows a proteolytic mat-
uration of IR that is insignificant in physiological conditions.
PACE4 is constitutively secreted into the extracellular media
(39) and localizes at the cell surface and in the extracellular
matrix (40). We investigated whether the PACE4-dependent
maturation of IR occurs in the secretory pathway or at the cell
surface.
Incubation of LoVo cells with the conditionedmedium from
HEK293 cells overexpressing the PC inhibitor EK4 reduced IRB
maturation but not substantially that of IRA (Fig. 4D). Further-
more, the multi-Leu peptide PACE4 inhibitor and its cell-im-
permeable derivative, two potent and relatively selective inhib-
itors (20-fold specificity over furin) (27), were equally efficient
in reducing the furin-independent maturation of IRB (Fig. 4E),
whereas the processing of IRA was marginally reduced. How-
ever, multi-Leu peptide PACE4 inhibitor did not reduce IR
processing in LoVo cells overexpressing furin (Fig. 4F). These
results show that the PC-dependent and furin-independent
maturation of IRB occurs at the cell surface. Furthermore, the
proteolytic maturation of IRB was increased by PACE4 added
extracellularly (Fig. 4G), and in that case the slow migrating
proform of IRB disappeared completely, whereas that of IRA
was only slightly reduced. As a control, PC5/6A added extracel-
lularly similarly increased the maturation of both IR isoforms
(Fig. 4H). These results demonstrate that PACE4 possesses the
ability to selectively process the cell surface-exposed proform
of IRB into its mature form. Taken together, our results argue
that the furin-independent maturation of IRB involves PACE4
and takes place at the cell surface.
Furin Inhibition Reduces IRAMaturation—Most cells simul-
taneously express both IR isoforms. We investigated whether
the proportion of mature IRA and IRB could be modified by
manipulating the PC activity. Differently tagged IR isoforms
were used to distinguish IRA from IRB in cotransfection exper-
iments. LoVo cells were cotransfected with IRAGFP and IRB in
the absence or presence of furin. As expected, only mature IRB
was detected in the absence of furin, and furin expression
increased the maturation of both IRAGFP and IRB (Fig. 5A, left
panel). A similar experimentwas performedbyusingHeLa cells
cotransfected with IRAGFP and IRB in the absence or presence
of the furin-specific shRNA. Furin knockdown reduced the
amount of mature IRAGFP but not that of IRB (Fig. 5A, right
panel). These experiments indicate that reducing the furin
activity preferentially diminished the proteolytic maturation of
IRA over that of IRB.
To avoid cotransfecting IR with furin-specific shRNA, we
tested commercial PC inhibitors for their ability to alter the
maturation of both IR isoforms to different extents. The dose
effect of the cell-permeable PC inhibitor Phac-RVR-4-Amba
(41) on the proteolytic maturation of both proIR isoforms was
investigated in HeLa cells that independently overexpressed
IRA and IRB. The maximal inhibition of IRA maturation was
obtained with a concentration of Phac-RVR-4-Amba as low as
0.5 M, whereas a concentration 10 times higher was necessary
to inhibit IRB maturation to the same extent (Fig. 5B). As a
result, with 0.5 M of Phac-RVR-4-Amba, the maturation of
IRAwas significantly more reduced than that of IRB (reduction
by 53  5 and 22  7% of the maturation of IRA and IRB
FIGURE 3. The involvement of PCs other than furin in IR maturation. A,
LoVocells expressingeither IRAor IRBwere treatedornotwithdec-RVKR-cmk
(RVKR; 5M) for 12 h. The IR was analyzed by immunoblot with IR antibody,
and the lower panel is a long exposure of the immunoblot showing the
mature form of IR. B, furin activity was measured in the media of HeLa cells
overexpressing GRAPfurin together with empty vector, 1-PDX (PDX), or EK4
expression vectors (data are expressedasmeansS.D.;n5; themeanbasal
furin activity was set at 100. *, p  0.05; **, p  0.001; analysis of variance,
Bonferroni test). C, HeLa cells were cotransfected with either IRA or IRB
together with an empty plasmid, 1-PDX (PDX), or EK4. Left panel, the IR was
analyzed by immunoblot with IR antibody. Right panel, inhibitory effect of
1-PDX (PDX) or EK4 on the maturation of IRA and IRB in HeLa cells (data are
means S.D. expressed as the percentage of the basal maturation; n 6; *,
p0.01; **,p0.001;ns, not significant; analysis of variance, Bonferroni test).
D, LoVo cells were cotransfected with either IRA or IRB together with an
empty plasmid or EK4, and IR was analyzed as described for A.
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respectively; n  6; p  0.05; analysis of variance, Bonferroni
test).
When the two IR isoforms were coexpressed in HeLa cells,
Phac-RVR-4-Amba treatment reduced the maturation of IRA
and allowed the detection of its slow migrating proform,
whereas the maturation of IRB was poorly altered (Fig. 5C).
These results show that treatment with Phac-RVR-4-Amba is
as effective as furin-specific knockdown at reducing proteolytic
maturation of IRA without unduly modifying that of IRB.
Inhibition of IRA Maturation Differentially Alters IR-depen-
dent Insulin and IGF2 Signaling—We investigated the impact
of the PC inhibitor Phac-RVR-4-Amba on the signaling trig-
gered by IR agonists (insulin and IGF2). In HEK293 cells, IGF2
more efficiently stimulated the phosphorylation of IRA than
that of IRB, whereas the phosphorylation of both IR isoforms
was similarly stimulated by insulin (Fig. 6A). These results are
compatible with a higher IGF2 affinity for IRA in comparison
with IRB. As expected, in cells overexpressing both IR isoforms,
insulin and IGF2 increased IR phosphorylation, andPhac-RVR-
4-Amba slightly reduced the maturation of IR (Fig. 6, B andD).
However, Phac-RVR-4-Amba prevented more efficiently the
phosphorylation of IR induced by IGF2 than that induced by
insulin, which is in accordance with its greater inhibitory effect
on the maturation of IRA than on that of IRB. In HEK293 cells,
phosphorylation of endogenous Erk1/2 resembled that of IR,
i.e. it was stimulated by insulin, and IGF2 and Phac-RVR-4-
Amba prevented more efficiently the phosphorylation of
Erk1/2 induced by IGF2 than that induced by insulin (Fig. 6, B
andC). InHeLa cells, IR overexpression allowed insulin to stim-
ulate the phosphorylation of endogenous PKB, which was not
reduced by Phac-RVR-4-Amba treatment (Fig. 6, D and E).
Interestingly, PKB phosphorylation was stimulated by IGF2
even in the absence of IR overexpression, but Phac-RVR-4-
Amba treatment somehow still reduced this phosphorylation.
Taken together, these data demonstrate that Phac-RVR-4-
Amba, which is more efficient in reducing the maturation of
IRA than that of IRB, reduces some of the signals that are trig-
gered by IGF2 without altering insulin signaling.
Treatment with Phac-RVR-4-Amba Reduces Cellular Effects
of IGF-2—Because treatment with Phac-RVR-4-Amba reduced
intermediate signaling in IR mitogenic pathways, we analyzed
whether this compound could actually inhibit cell proliferation.
The proliferative effect of IGF2 on HEK293 cells did not neces-
FIGURE 4. The importance of PACE4 in IRmaturation. A, LoVo cells were cotransfected with IRA or IRB expression vector together with an empty vector ()
or with the indicated PC expression vector. B, LoVo cells were cotransfected with IRA or IRB together with an empty vector or with a PACE4 expression vector.
C, LoVo cells were cotransfected with IRB and PC7-specific shRNA (shPC7).D, LoVo cells expressing IRA or IRB were incubated for 12 hwith conditionedmedia
from HEK293 cells transfected with an empty plasmid or with EK4 expression vector. E, same as D except that cells were incubated with 50 M of multi-Leu
peptide PACE4 inhibitor (ML) or its cell-impermeable derivative (PEG8-ML). F, LoVo cells expressing furin and IRA or IRBwere treatedwith 50MofML.G, same
as D except that cells were incubated for 8 h with conditioned media from HEK293 cells transfected with a PACE4 expression vector. H, same as E except that
cells were incubated with conditioned media from HEK293 cells transfected PC5/6A expression vector. Each blot is representative of three independent
experiments. The IRwas analyzed by immunoblot with IR (A) or IR antibody, and PC7 position is indicated by PC7. Themiddle panel in C and the lower panels
in D and E are long exposures of the immunoblots showing the mature form of IR (IR).
TABLE 1
mRNA levels of PCs in different cell lines
Shown are the rawCt values (mean S.D.; n 4) collected for the expression of the
housekeeping gene (Rplp0) and the genes coding for furin, PACE4, PC5/6, and PC7
in the different cell lines used in this study.
Rplp0 Furin PACE4 PC5/6 PC7
Hek293 17.0 0.3 32.1 0.3 21.1 0.2 23.4 0.2 23.1 0.3
HeLa 15.2 0.3 32.5 0.2 23.6 0.4 Not detected 23.8 0.4
LoVo 14.8 0.4 Not tested 21.2 0.4 24.3 0.5 23.0 0.4
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sitate the overexpression of IR, although it was significantly
more pronounced in IR-overexpressing cells (Table 2). Con-
trarily, the proliferative effect of insulin was only observed in
HEK293 cells that overexpressed IR. In all situations, the pro-
liferation induced by IR agonists was abolished by Phac-RVR-
4-Amba treatment (Table 2). The impact of Phac-RVR-4-Amba
treatment on the metabolic response to IGF2 and insulin was
studied in 3T3L1 adipocytes taken as a model of insulin target
cells. As expected for cells that express both IR isoforms (Fig.
2D), Phac-RVR-4-Amba treatment reduced the maturation of
IR and the IGF2- and insulin-dependent phosphorylation of
PKB (Fig. 7A) in a manner essentially comparable with those
described previously (Fig. 6, B,D, and E). In addition, the IGF2-
dependent GLUT4 plasma membrane translocation and glu-
cose uptake were significantly reduced by Phac-RVR-4-Amba
treatment, whereas those stimulated by insulinwere not altered
(Fig. 7, B and C). These results demonstrate that Phac-RVR-4-
Amba treatment reduces the proliferative andmetabolic effects
of IGF2, whereas it only reduces the proliferative effect of
insulin.
DISCUSSION
The present study demonstrates that the IRB proform
exposed at the cell surface is efficiently processed to its mature
form by PACE4. Furthermore, these data highlight the possibil-
ity of reducing IRA maturation and its associated mitogenic
signals without unduly affecting the metabolic signals emanat-
ing from IRB.
Our data do not detract from the previously reported impor-
tance of furin in the maturation of IR (9–11). Indeed, we used
knockdown and re-expression experiments to demonstrate
that furin is the primary PC involved in the maturation of IRA
and IRB. However, the specific furin deficiency (LoVo cells or
specific knockdown) or PC inhibition (chemical inhibitors or
overexpression of PDX and EK4) led to a more important
reduction in the maturation of IRA than that of IRB. These
results emphasize that the proteolytic maturation of IRA is
more under the control of furin than that of IRB.
As reported by others (28), we confirm thatwhenproIR is not
efficiently cleaved by furin in the Golgi apparatus, it is still
routed to the cell surface. However, in addition to this, by using
PC inhibitors that do not penetrate the cell (treatmentwith EK4
or with the cell impermeable multi-Leu peptide PACE4 inhib-
itor), we provide arguments indicating that the proform of IRB
FIGURE5.Thepreferential reductionof IRAmaturationbyPC inhibitor.A,
LoVo and HeLa cells were transfected with GFP-tagged IRA (IRAGFP) and
untagged IRB together with an empty plasmid (), furin (fur), untargeted
shRNA (shscr), or furin-specific shRNA (shfur). B, HeLa cells expressing IRA or
IRB were incubated with the indicated concentrations of Phac-RVR-4-Amba
(RVR) for 14 h. To better visualize the effect of Phac-RVR-4-Amba treatment
(RVR; 0.5M for 14 h) on IRA and IRBmaturation, lysates fromHeLa cells were
run side by side on SDS-PAGE (lower panel). C, HeLa cells were cotransfected
with IRA Flag and IRBHis6 and treatedwith Phac-RVR-4-Amba (RVR; 0.5M for
14h). Eachblot is representativeof at least three independent experiments. IR
was analyzed by immunoblot (IB) with IR, IR Flag M2 (flag), or His6 (6his)
antibodies.
FIGURE6.The reductionof IR-dependent IGF2signalingbyaPC inhibitor.
A, HEK293 cells overexpressing IRA or IRB were stimulated with the indicated
concentrations of IGF2 or insulin for 10 min. B, HEK293 cells overexpressing
IRA and IRB or those transfected with the empty vector were incubated with
Phac-RVR-4-Amba (RVR; 0.5 M) for 14 h and then stimulated with insulin (1
nM) or IGF2 (5 nM) for 10min. IR, phospho-IR (pIR), Erk1/2, andphospho-Erk1/2
(pErk1/2) were analyzed by immunoblot. C, pErk1/2 was analyzed by ELISA in
the lysates of HEK293 cells overexpressing IRA and IRB. D, HeLa cells were
transfected and treated as described for B, and IR, phospho-IR (pIR), PKB, and
phospho-PKB (pPKB) were analyzed by immunoblot. E, pPKBwas analyzed by
ELISA in the lysates of HeLa cells overexpressing IRA and IRB. Data are
expressed as means S.D., and basal Erk1/2 and PKB phosphorylation were
set at 1. *, p 0.05 (Mann-Whitney); n 6.
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exposed at the cell surface is prone to a PC-dependent (and
furin-independent) maturation. We also show that PACE4
(overexpressed or added extracellularly) is the only PC that has
the peculiar property of increasing the maturation of IRB with-
out changing that of IRA. These results are in accordance with
the location and action of PACE4 at the cell surface and in the
extracellular matrix (40, 42). In brief, when the intracellular
furin-dependent maturation of IR is reduced, both proIR iso-
forms are exposed at the cell surface where only the proform of
IRB is efficiently matured by PACE4. Along the same lines,
angiopoietin-like 3 was shown to be matured intracellularly by
furin action and at the cell surface by PACE4 (43). The ability of
PACE4 to process the IRB proform at the cell surface could
explain the efficient maturation of IR in furin knock-out mouse
livers (13). Indeed, in the liver, PACE4 is highly expressed (13,
44), and IRB is the preponderant IR isoform (16).
Speculation can bemade on the elements that are potentially
involved in the differential cleavage of the two IR isoforms by
PACE4. The absence or presence of exon 11 in IRA and IRB,
respectively, can directly alter the recognition of IR by PACE4.
Indeed, as determined for furin (26), PACE4 recognitionmotifs
could stretch far from the cleavage site, and in the case of IR, the
recognition motif could encompass the exon 11. Our result
showing that the two proIR isoforms exposed at the cell surface
are similarly cleaved by extracellular of PC5/6A suggests that
their accessibility to the extracellular PCs is not fundamentally
different. However, the two IR isoforms are believed to be local-
ized in different plasma membrane microdomains (23, 24);
therefore, their membranemicroenvironment can be different.
Because PACE4 localizes at the cell surface through interaction
with heparin sulfate proteoglycans (40) or tissue inhibitor of
metalloproteinases (42), the composition of the IR membrane
microenvironment could affect the accumulation of PACE4
and thereby regulate IR cleavage. The fact that PACE4 cleaves
IRB at the cell surface and not in the constitutive secretory
pathway could be related to the preference of PACE4 for cleav-
ing substrates at neutral pH (14, 40). It is also conceivable that
PACE4 responsible for IRB maturation is inactive in the secre-
tory pathway. Indeed, it was previously suggested that PACE4
activation could take place at the cell surface (45).
In cells expressing the two IR isoforms, a specific furin
knockdown efficiently reduces the maturation of IRA and
poorly alters that of IRB, which results in a lower quantity of
mature IRA. To simplify our experimental system, we tested
commercial PC inhibitors for their ability to reduce the proteo-
lytic maturation of IRA and not that of IRB, and we found that
treatment of cells with low doses of Phac-RVR-4-Amba allows
reaching that goal. The ability of this PC inhibitor to differently
alter the maturation of the two IR isoforms was exploited to
modulate IR-dependent metabolic and mitogenic signaling.
The phosphorylation of IRA and IRB is similarly stimulated by
insulin,whereas IGF2moreeffectively stimulates thephosphor-
ylation of IRA than that of IRB. This finding is consistent with
previous data demonstrating that IGF2 has a higher affinity for
IRA than IRB (17, 18) and implies that IRA is responsible for the
mitogenic signals emanating from IR (16). In cells expressing
both IR isoforms, the IGF2-stimulated phosphorylation of IR,
was reduced by Phac-RVR-4-Amba treatment, whereas the
insulin effect was poorly altered. Furthermore, Phac-RVR-4-
Amba treatment significantly reduces the IR-dependent phos-
phorylationof Erk1/2 triggeredby IGF2,whereas thephosphor-
ylation of Erk1/2 and PKB triggered by insulin was not
compromised. These results validate the idea that it is possible
to orient IR signaling through a pharmacological manipulation
of proIR isoforms maturation; by reducing IRA maturation
without modifying that of IRB, it is possible to reduce the IR
mitogenic signals (triggered by IGF2 and emanating from IRA)
TABLE 2
Cell proliferation measured by BrdU incorporation
Serum-starved nonconfluent HEK293 cells were left untreated (control) or treated with Phac-RVR-4-Amba (RVR; 0.5 M) and then incubated with insulin (1 nM) or IGF2
(5 nM) in presence of BrdU for 16 h. BrdU incorporation was measured as described under “Experimental Procedures.” The data are expressed as means S.D., and values
obtained in the control situations (without RVR) are arbitrarily set at 100.
Control RVR
Control Insulin IGF2 Control Insulin IGF2
HEK293 100 7 105 8 118 6a 100 3 98 6 100 3
HEK293 IRA	 IRB 100 3 113 9a 127 5a 100 4 98 4 97 5
a p 0.05 versus the control situation (Mann-Whitney; n 4).
FIGURE 7. Phac-RVR-4-Amba does not reduce the metabolic effect of
insulin.A, 3T3L1 adipocyteswere incubatedwith Phac-RVR-4-Amba (RVR; 0.5
M) for 14 h and then stimulated with IGF2 (5 nM) or insulin (1 nM) for 10min.
IR, phospho-IR (pIR), PKB, and phospho-PKB (pPKB) were analyzed by immu-
noblot. B and C, 3T3L1 adipocytes were incubated with Phac-RVR-4-Amba as
described for A, and the cell surface expression of GLUT4 (B) and glucose
uptake (C) was stimulated by 10 nM IGF2 or insulin were measured. The data
are expressedasmeansS.D., andbasal cell surfaceexpressionofGLUT4and
glucose uptake were set at 1. *, p 0.01 (Mann-Whitney); n 6.
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without modifying the metabolic signals (triggered by insulin).
Clearly, the unprocessed IRA that is exposed at the cell surface
does not interferewith IR signaling, which is in accordancewith
data reporting that the signaling ability of the proIR exposed at
the cell surface is severely reduced (28, 46–48). Treatmentwith
Phac-RVR-4-Amba not only reduces intermediate signaling in
IR mitogenic pathways but also inhibits IR-dependent cell pro-
liferation, which is in line with previous data demonstrating
that furin inhibition attenuates critical properties of tumor cells
(35, 49–51). The measure of GLUT4 plasma membrane trans-
location and glucose uptake using 3T3 L1 adipocytes taken as a
model of insulin target cells confirm that the metabolic effects
of insulin are not altered by Phac-RVR-4-Amba treatment.
As suggested, exacerbated IRA signaling may represent an
important mechanism of resistance to various anticancer ther-
apies and should therefore be considered to be a target in cancer
therapy (16). Our results indicating that furin inhibition is an
effective strategy to block signaling through IRA without alter-
ing the metabolic effects of insulin will pave the way for new
opportunities to target the IRA signaling in cancer in a specific
fashion.
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